Arming antibodies: prospects and challenges for immunoconjugates

@article{Wu2005ArmingAP,
  title={Arming antibodies: prospects and challenges for immunoconjugates},
  author={Anna M. Wu and Peter D. Senter},
  journal={Nature Biotechnology},
  year={2005},
  volume={23},
  pages={1137-1146}
}
  • A. WuP. Senter
  • Published 1 September 2005
  • Biology, Chemistry
  • Nature Biotechnology
Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)—are becoming a significant component of anticancer treatments. By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector molecules, immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional… 

Technology Insight: cytotoxic drug immunoconjugates for cancer therapy

This Review examines optimal design, the lessons learned from clinical immunoconjugate development, and the promising agents in early preclinical/clinical development for the treatment of cancer.

Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

The design of ADCs is reviewed, how ADCs can be exploited to overcome multiple drug resistance (MDR) is focused on, and if appropriate solutions are presented, ADCs will play a more important role in the development of targeted therapeutics against cancer in the next years.

Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.

ANTIBODY DRUG CONJUGATES: A LEAP AHEAD IN CANCER TREATMENT

To achieve the goal of highly improved therapeutic efficacy and reduced toxicity, each component of an ADC i.e. the MAb, linker and the drug needs to be considered in context of targeted antigen.

Immunoconjugates Against Solid Tumors: Mind the Gap

  • A. Ricart
  • Biology, Medicine
    Clinical pharmacology and therapeutics
  • 2011
Further economic evaluation might be necessary before this approach can replace the current standards of care in clinical practice, and new small antibody formats, such as single‐chain Fv, Fab, and diabodies, may improve penetration within tumor masses.

Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.

Findings from quantitative evaluations of the tumor targeting properties of antibodies and of small organic ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics.

Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance?

An overview of modern approaches to cancer treatment, from first-generation systemically delivered chemotherapeutics through the contemporary use of molecularly-targeted small molecules and biologics, to the culmination of both of these approaches—the ADC.

Site-specific antibody drug conjugates for cancer therapy

Various site-specific conjugation strategies that are currently used for the production of ADCs are reviewed, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugations through glycotransferases and transglutaminases.

Large Molecule Therapeutics Antibody-Based Delivery of IL 2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice

The therapeutic effect of antibody-based pharmacodelivery of cemadotin, a cytotoxic drug, and IL2, a strong proinflammatory cytokine is investigated, which led to tumor eradication in the C1498 syngeneic mouse model of acute myelogenous leukemia.

Antibody-targeted drugs and drug resistance--challenges and solutions.

...

References

SHOWING 1-10 OF 114 REFERENCES

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

  • P. WallaceP. Senter
  • Biology, Chemistry
    Methods and findings in experimental and clinical pharmacology
  • 1994

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

  • N. Damle
  • Biology, Chemistry
    Expert opinion on biological therapy
  • 2004
Gemtuzumab ozogamicin is the first clinically validated cytotoxic immunoconjugate in which a humanised anti-CD33 antibody is linked to a derivative of calicheamicin, and is indicated for the treatment of elderly patients with relapsed acute myeloid leukaemia.

Designer genes: recombinant antibody fragments for biological imaging.

  • A. WuP. Yazaki
  • Biology
    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology
  • 2000
Ease of engineering and expression, combined with novel specificities that will arise from advances in genomic and combinatorial approaches to target discovery, will usher in a new era of recombinant antibodies for biological imaging.

Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.

It is demonstrated that the cleavable RIC substrate is able to bind to tumor antigens and localize within human tumor xenografts and that accelerated systemic clearance can be induced with beta-lactamase.

Efficient cancer therapy with a nanobody-based conjugate.

In vivo studies demonstrated that the nanobody-enzyme conjugate had an excellent biodistribution profile and induced regressions and cures of established tumor xenografts, making nanobodies promising vehicles for new generation cancer therapeutics.

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.

Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.

The concept in vivo in tumored mice of amplfication targeting has now been shown to be feasible and signal amplification has not yet been convincingly demonstrated and amplification targeting will require further studies for optimization.

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

To extend and optimize their future clinical RIS utility with radiometals, these recombinant antibody fragments were conjugated with the macrocycle 1,4,7,10-tetraazacyclodododecane N,N',N' ',N' "-Tetraacetic acid (DOTA) and labeled with 111In.

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

Current status of therapy of solid tumors.

  • Y. JhanwarC. Divgi
  • Medicine, Biology
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2005
This review will describe seminal studies that have paved the way to an understanding of radioimmunotherapy in solid tumors and the authors' views of the future of this promising cancer therapy will be presented.
...